Treatment Strategies and Outcomes in Diffuse Large B‐cell Lymphoma of the Elderly: A Danish Population‐based Cohort Study of 1,011 Patients

Abstract

from CLL11 (n = 132), CLL1 (n = 3), CLL5 (n = 1), CLL7 (n = 3), CLL8(n = 2), CLL9 (n = 9), and CLL10 (n = 2). Median age was 82 years (range [80][81][82][83][84][85][86][87][88][89][90]. Concomitant diseases were present in 99% of the pts and median cumulative illness rating scale (CIRS) score was 8 (0-18).Median creatinine clearance was 46 mL/min (range 17-99 mL/min).Distribution of CLL-IPI risk groups was as follows: 6% low, 19% intermediate, 61% high, and 14% very high. Most pts had Binet stage B (36%) or C (43%).Chemoimmunotherapy with chlorambucil plus obinutuzumab (CLB-OB) or chlorambucil plus rituximab (CLB-R) was administered to 61 (40%) and 56 (37%) pts, respectively. Remaining pts received chlorambucil alone (CLB, n = 19), fludarabine (F, n = 10), F/cyclophosphamide (FC, n = 1), FC/rituximab (FCR, n = 2), or bendamustine/rituximab (BR, n = 3). Rates of grade 3 or 4 neutropenia and infections were 35% and 13%, respectively. Premature treatment discontinuations occurred in 15% of cases and were mostly due to adverse events. The total overall response rate was 92% with 13% Results: A decline in age-standardized incidence until the mid-1990s was primarily driven by males >50 years. There was, however, evidence of a slight increase in incidence among children and young adults (≤34 years). The 1-year RSRs (95% confidence interval; CI)for males aged 55, 65, 75, and 85, diagnosed

Prognostic significance of infectious episodes occurring during first‐line therapy for diffuse large B‐cell lymphoma ‐ A nationwide cohort study

“…A further contribution to this observation may be the increasing dose intensity given to elderly patients with DLBCL in more recent years. We recently showed that anthracycline containing therapy was administered in 71% of patients above 74 years, in the period from 2008 to 2012, compared to only 57% between 2003 and 2007 37 . The more frequent use of anthracyclines in patients above 74 years seen in recent years probably reflects a combination of factors, such as a more fit elderly population, better supportive strategies, and a consequent shift toward a more curatively intended approach in the elderly.…”

Construction of homologous cancer cell membrane camouflage in a nano-drug delivery system for the treatment of lymphoma

“…At present, the incidence of NHL demonstrates a significant upward trend in different stages of age [1]. Certain patients with NHL can achieve complete remission after a short duration of chemotherapy under the R-CHOP regimen [2]. Unfortunately, about 50% of such patients will relapse, and the 3-year overall survival rate after recurrence is about 30% [3].…”